Kim YH, Bagot M, Pinter-Brown L, et al. Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study. ASH 59th Annual Meeting & Exhibition, abstract 817.
Fysieke inactiviteit de grootste modificeerbare risicofactor in de geneeskunde
jan 2024 | Leukemie, Lymfoom, MDS, MM, MPN